A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
- Lymphoma, Large B-Cell, Diffuse
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 594
- Started
- 11 April 2025
- Main results due
- 13 December 2027
- Study sites
- 146
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues. * Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale. * Has received no prior treatment for their DLBCL. * Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART). * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization. * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of transformation of indolent disease to DLBCL. * Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma. * Has Ann Arbor Stage I DLBCL. * Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication. * Has clinically significant pericardial or pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a demyelinating form of Charcot-Marie-Tooth disease. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Has ongoing corticosteroid therapy. * Known additional malignancy that is progressing or has required active treatment within the past 2 years. * Known active central nervous system (CNS) lymphoma. * Has active autoimmune disease that has required systemic treatment in the past 2 years. * Has active infection requiring systemic therapy. * Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection. * Has history of stem cell/solid organ transplant.
What this study is about
In the sponsor’s own words, from the registry.
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.
The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Study sites(146)
Infirmary Cancer Care ( Site 0157)
Mobile, Alabama, United States
Recruiting
Ironwood Cancer & Research Centers ( Site 0204)
Chandler, Arizona, United States
Recruiting
Palo Verde Cancer Specialists ( Site 0105)
Glendale, Arizona, United States
Recruiting
City of Hope - Phoenix ( Site 0202)
Goodyear, Arizona, United States
Recruiting
Genesis Cancer and Blood Institute ( Site 0193)
Hot Springs, Arkansas, United States
Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135)
Burbank, California, United States
Recruiting
City of Hope Comprehensive Cancer Center ( Site 0191)
Duarte, California, United States
Recruiting
Bass Medical Group ( Site 0123)
Walnut Creek, California, United States
Recruiting
Rocky Mountain Cancer Centers (RMCC) ( Site 8001)
Aurora, Colorado, United States
Recruiting
Colorado West Healthcare System-Grand Valley Oncology ( Site 0165)
Grand Junction, Colorado, United States
Recruiting
Medical Oncology Hematology Consultants (MOHC) ( Site 8007)
Newark, Delaware, United States
Recruiting
Georgetown University Medical Center ( Site 0117)
Washington D.C., District of Columbia, United States
Recruiting
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130)
Boca Raton, Florida, United States
Recruiting
Baptist MD Anderson Cancer Center ( Site 0176)
Jacksonville, Florida, United States
Recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 0140)
Miami Beach, Florida, United States
Recruiting
Mid Florida Hematology and Oncology Center ( Site 0152)
Orange City, Florida, United States
Recruiting
Beacon Cancer Care ( Site 0142)
Post Falls, Idaho, United States
Recruiting
University of Chicago Medical Center ( Site 0126)
Chicago, Illinois, United States
Recruiting
Illinois Cancer Care ( Site 7005)
Peoria, Illinois, United States
Recruiting
University of Iowa-Holden Comprehensive Cancer Center ( Site 0139)
Iowa City, Iowa, United States
Recruiting
Mission Blood & Cancer Care ( Site 0114)
Waukee, Iowa, United States
Recruiting
Saint Elizabeth Medical Center Edgewood ( Site 0141)
Edgewood, Kentucky, United States
Recruiting
Baptist Health Hardin ( Site 0154)
Elizabethtown, Kentucky, United States
Recruiting
Baptist Health Lexington ( Site 0127)
Lexington, Kentucky, United States
Recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185)
Louisville, Kentucky, United States
Recruiting
Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180)
Baton Rouge, Louisiana, United States
Recruiting
Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209)
Monroe, Louisiana, United States
Recruiting
Ochsner Clinic Foundation ( Site 0189)
New Orleans, Louisiana, United States
Recruiting
Louisiana State University Health Sciences Shreveport ( Site 0195)
Shreveport, Louisiana, United States
Recruiting
Beth Israel Deaconess Medical Center ( Site 0161)
Boston, Massachusetts, United States
Recruiting
Dana Farber Cancer Institute ( Site 0111)
Boston, Massachusetts, United States
Recruiting
Minnesota Oncology Hematology (MNO) ( Site 8004)
Burnsville, Minnesota, United States
Recruiting
Bozeman Health Deaconess Hospital ( Site 0183)
Bozeman, Montana, United States
Recruiting
NHO Revive Research Institute, LLC ( Site 0121)
Lincoln, Nebraska, United States
Recruiting
University Of Nebraska Medical Center ( Site 0110)
Omaha, Nebraska, United States
Recruiting
Atlantic Health Morristown Medical Center ( Site 0163)
Morristown, New Jersey, United States
Recruiting
Valley Health Systems - Ridgewood Campus ( Site 0125)
Paramus, New Jersey, United States
Recruiting
Erie County Medical Center ( Site 0175)
Buffalo, New York, United States
Completed
Roswell Park Cancer Institute ( Site 0192)
Buffalo, New York, United States
Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208)
Mineola, New York, United States
Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108)
New York, New York, United States
Recruiting
SUNY Upstate Cancer Center ( Site 0178)
Syracuse, New York, United States
Recruiting
Optum Medical Care, PC ( Site 0122)
Westbury, New York, United States
Recruiting
University of North Carolina Medical Center ( Site 0136)
Chapel Hill, North Carolina, United States
Recruiting
Novant Health Presbyterian Medical Center ( Site 0177)
Charlotte, North Carolina, United States
Recruiting
Novant Health Forsyth Medical Center ( Site 0206)
Winston-Salem, North Carolina, United States
Recruiting
University of Cincinnati Medical Center ( Site 0156)
Cincinnati, Ohio, United States
Recruiting
University Hospitals of Cleveland ( Site 0155)
Cleveland, Ohio, United States
Recruiting
Fairview Hospital-Moll Cancer Center ( Site 0198)
Cleveland, Ohio, United States
Recruiting
Cleveland Clinic Main ( Site 0101)
Cleveland, Ohio, United States
Recruiting
Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199)
Mayfield Heights, Ohio, United States
Recruiting
Providence Portland Medical Center ( Site 0120)
Portland, Oregon, United States
Recruiting
Providence Oncology and Hematology Clinic Westside ( Site 0179)
Portland, Oregon, United States
Recruiting
Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131)
Philadelphia, Pennsylvania, United States
Recruiting
Temple University Hospital ( Site 0133)
Philadelphia, Pennsylvania, United States
Recruiting
Alliance Cancer Specialists (ACS) ( Site 8010)
Sellersville, Pennsylvania, United States
Recruiting
Cancer Care Associates Of York ( Site 0174)
York, Pennsylvania, United States
Recruiting
Medical University of South Carolina ( Site 0153)
Charleston, South Carolina, United States
Recruiting
Tennessee Cancer Specialists ( Site 7004)
Knoxville, Tennessee, United States
Recruiting
SCRI Oncology Partners ( Site 7002)
Nashville, Tennessee, United States
Recruiting
Showing 60 of 146 sites — filter to narrow it down. 144 of the 146 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06890884. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me